Target
$372.69 → $372.42
Current stock research snapshot · 7/8/26 49 days old
WSTWest Pharmaceutical Services
Investment conviction●●○○○2 of 5 · current snapshot
Research target$372.42Current stock price target
Investment thesis statusINTACTLast reviewed 7/8/26
Market cap$25.16BSnapshot value · 7/8/26
Research history
See all WST changes ↗What changed
Purest pick-and-shovel of injectables: elastomer closures + RTU components + self-injection devices. GLP-1 demand consumed high-value syringe/stopper capacity faster than suppliers can validate. Annex 1 RTU conversions additive.
GLP-1 injectable dominance (each pen bundles glass + elastomer + device); Medicare GLP-1 Bridge (live July 1 2026 ~$50 copay); ~2031 patent cliff (biosimilars still need fill-finish); SmartDose 3.5ml divestiture to AbbVie mid-2026.
Oral GLP-1 bypassing sterile bottleneck (Lilly Foundayo launched April 2026); GLP-1 ~20% exposure as swing factor; capacity coming online 2026-2027 (finite tightness); Novo/Catalent in-housing.
Neutral — No significant X discussion found in the last 30 days. [X search Aug 2026]
Snapshot · 7/8/26🟡 Mixed · ins-$1.1M · 13F 9+/16-×0.5 · short↓0.24
Snapshot · 7/8/26